HUNTSVILLE, ALABAMA, Wednesday, September 10th, 2025 -- Score Pharma Inc., a biopharmaceutical
company pioneering next-generation therapeutic antibody platforms, announced today that it was
selected as a finalist in the title round pitch competition at ConvergeSouth 2025 and participated as an
exhibitor at the event held in Winston-Salem, North Carolina.

ConvergeSouth, the Southeast’s premier technology and innovation conference, brings together
founders, investors, and industry executives to highlight high-growth companies shaping the future of
their sectors. Score Pharma Inc.’s advancement to the final round of pitches reflects the strength of its
innovation and the scalability of its development strategy.

As an exhibitor, the company presented its differentiated approach to antibody drug development with
initial targets focused on oncology, drawing significant engagement from investors and potential
strategic partners.

“Being named a finalist at ConvergeSouth underscores both the scientific and commercial potential of
our platform,” said Bruce Edward Jones, Ph.D., Founder & Chief Executive Officer of Score Pharma Inc.
“We are committed to advancing therapies that deliver meaningful patient impact while creating long-term value for our investors.”

Score Pharma Inc.’s recognition at ConvergeSouth 2025 represents a milestone in its growth trajectory
and validates its position as an emerging leader in the biopharmaceutical sector.

About Score Pharma Inc.

Score Pharma Inc. is dedicated to developing new, more potent antibody therapeutics by transforming
existing clinically proven antibody therapeutics for an improved patient response. Through a science-driven strategy and disciplined execution, the company aims to deliver transformative outcomes for
patients and sustainable returns for shareholders.

Media Contact
Kip Wolf, Chief Operating Officer & Vice President, Business Development
kwolf@scorepharma.com
+1 717-376-6672